Eloxatin
Early-stage
Chinese Academy of Medical SciencesPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Early-stage cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IMMUNOGLOBULIN G1, ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN MONOCLONAL MEDI9447 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI9447 .LAMBDA.-CHAIN, DIMER MedImmune LLC | Phase 2 | B |
Ibrutinib MedImmune LLC | Phase 2 | B |
Durvalumab MedImmune LLC | Phase 2 | B |
Monalizumab MedImmune LLC | Phase 2 | B |
Danvatirsen MedImmune LLC | Phase 2 | B |
PEGASPARGASE Chinese Academy of Medical Sciences | Phase 2 | CCC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →